<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="management of this crisis. Considerable scientific progress was recorded regarding" exact="SARS-CoV-2 infection" post="in terms of genomic structure, diagnostic tools, viral transmission,"/>
 <result pre="therapeutics was also included. In addition, a comprehensible overview of" exact="SARS-CoV-2 infection" post="in terms of general description and structure, mechanism of"/>
 <result pre="perspective. This review plans to offer a comprehensible overview of" exact="SARS-CoV-2 infection" post="in terms of general description and structure, mechanism of"/>
 <result pre="even death [31]. Lungs were considered the main target for" exact="SARS-CoV-2 infection," post="but other injured organs were also described after encounter"/>
 <result pre="the present review, anosmia was considered an uncommon symptom of" exact="SARS-CoV-2 infection," post="but according to the latest studies, this symptom became"/>
 <result pre="factor (TNF-Î±), and vascular endothelial growth factor (VEGF) [28,43]. Additionally," exact="SARS-CoV-2 infection" post="may cause cell pyroptosis within macrophages and lymphocytes, which"/>
 <result pre="caused severe acute lung injury in the early stages of" exact="SARS-CoV infection." post="It is believed that the antibody-dependent injuries are owing"/>
 <result pre="still remains unclear, is the decreased susceptibility of children to" exact="SARS-CoV-2 infection" post="as compared with the adult population. Even though an"/>
 <result pre="with the adult population. Even though an age-dependent susceptibility to" exact="SARS-CoV-2 infection" post="was established, a valid explanation for these disparities is"/>
 <result pre="is considered at this point the most promising treatment for" exact="SARS-CoV-2 infection" post="on the basis of the latest outcomes acquired within"/>
 <result pre="by Gilead Sciences, Inc. as an antiviral candidate against the" exact="Ebola" post="virus, but it also proved to be highly efficient"/>
 <result pre="form, interfering with the action of the viral RdRp of" exact="Ebola" post="virus via insertion into the newly nascent viral RNA"/>
 <result pre="understanding of the antiviral mechanism of action of RDV in" exact="SARS-CoV-2 infection" post="[67,68,69]. In order to investigate whether this mechanism of"/>
 <result pre="phase III clinical trials on healthy volunteers and patients with" exact="Ebola" post="virus infection asserted the pharmacokinetic properties and a safety"/>
 <result pre="COVID-19 patients [78]. These latest data regarding RDV efficacy against" exact="SARS-CoV-2 infection" post="are stimulating, although the gaps concerning its safety profile"/>
 <result pre="RDV administration or are in fact consequences/complications determined by the" exact="SARS-CoV-2 infection" post="[71]. One of the randomized, double-blind, placebo-controlled, multicentre clinical"/>
 <result pre="it is unclear what causes itâ€&quot;the medication administered or the" exact="SARS-CoV-2 infection," post="thus liver protection would do no harm); As RDV"/>
 <result pre="CQ [95,96]; and (v) HCQ apparently offered no protection against" exact="SARS-CoV-2 infection" post="(results of a large healthcare Israelian database analysis) [97]."/>
 <result pre="based on several premises: azithromycin proved in vitro activity against" exact="Ebola" post="and Zika viruses, as well as a preventive effect"/>
 <result pre="by WHO that evaluates these compounds as possible therapy against" exact="SARS-CoV-2 infection;" post="the HERO-HCQ, a study sponsored by the National Institutes"/>
 <result pre="clinical data regarding the use of CQ and HCQ in" exact="SARS-CoV-2 infection" post="are not considered robust [102], and EMA did not"/>
 <result pre="oral lopinavir (400 mg) associated with ritonavir (200 mg) in" exact="SARS-CoV-2 infection." post="At the end of their study, there was no"/>
 <result pre="patients with severe viral infections such as EBV, H1N1, and" exact="Ebola" post="[143]. A recent cohort study evaluated the effect of"/>
 <result pre="Considering the imperative need to find an effective treatment against" exact="SARS-CoV-2 infection" post="(which is lacking at present), administration of immune â€œconvalescentâ€�"/>
 <result pre="assessed the following directions: (i) treatment for mild forms of" exact="SARS-CoV-2 infection;" post="(ii) treatment for moderately ill patients; (iii) as rescue"/>
 <result pre="still unknown if the hemostatic disorders are a cause of" exact="SARS-CoV-2 infection" post="or a repercussion of the cytokine storm that triggers"/>
 <result pre="the infection spread repression); and (v) the clinical impact of" exact="SARS-CoV-2 infection" post="(characteristic symptomatology, onset, clinical stages, complications) is mostly described,"/>
 <result pre="constantly being updated. The urge to find a therapy for" exact="SARS-CoV-2 infection" post="determined the occurrence of multiple therapeutic alternatives, such as"/>
 <result pre="At present, remdesivir is considered the most promising therapy for" exact="SARS-CoV-2 infection" post="being already included in the interim guidelines for COVID-19"/>
 <result pre="is debatable at this point. The use of lopinavir/ritonavir against" exact="SARS-CoV-2 infection" post="determined controversial results; that is, according to some clinical"/>
 <result pre="ruloxitinib, and so on) should be recommended as therapy for" exact="SARS-CoV-2 infection" post="only when the laboratory results indicate a potential â€œcytokine"/>
 <result pre="Hepatol.20208131710.14218/JCTH.2020.0001932274341 43.HongE.H.SongJ.H.KangK.B.SungS.H.KoH.J.YangH.Anti-Influenza Activity of Betulinic Acid From Zizyphus Jujuba on" exact="Influenza" post="A/PR/8 VirusBiomol. Ther.20152334534910.4062/biomolther.2015.019 44.KulkarniR.Antibody-Dependent Enhancement of Viral InfectionsDyn. Immune"/>
 <result pre="Transmission and Control of COVID-19 EpidemicsNat. Med.202010.1038/s41591-020-0962-9 46.XieZ.Pay attention to" exact="SARS-CoV-2 infection" post="in childrenPediatric Investig.202041410.1002/ped4.12178 47.LiguoroI.PilottoC.BonanniM.FerrariM.E.PusiolA.NocerinoA.VidalE.CogoP.SARS-COV-2 infection in children and newborns:"/>
 <result pre="Novel Coronavirus (2019-nCoV) in VitroCell Res.20203026927110.1038/s41422-020-0282-032020029 62.TchesnokovE.P.FengJ.Y.PorterD.P.GÃ¶tteM.Mechanism of Inhibition of" exact="Ebola" post="Virus RNA-Dependent RNA Polymerase by RemdesivirViruses20191132610.3390/v1104032630987343 63.DainaA.MichielinO.ZoeteV.wissADME: A Free"/>
 <result pre="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/(accessed on 25 April 2020) 117.GoriT.LelieveldJ.MÃ¼nzelT.Perspective: Cardiovascular Disease and the" exact="Covid-19" post="PandemicBasic Res. Cardiol.20201153210.1007/s00395-020-0792-432277299 118.BassettiM.GiacobbeD.R.AlibertiS.BarisioneE.CentanniS.De RosaF.G.Di MarcoF.GoriA.GranataG.MikulskaM.et al.Balancing Evidence and"/>
 <result pre="121.LewW.ChenX.KimC.U.Discovery and Development of GS 4104 (Oseltamivir): An Orally Active" exact="Influenza" post="Neuraminidase InhibitorCurr. Med. Chem.2000766367210.2174/092986700337488610702632 122.DaviesB.E.Pharmacokinetics of Oseltamivir: An Oral"/>
 <result pre="Oseltamivir: An Oral Antiviral for the Treatment and Prophylaxis of" exact="Influenza" post="in Diverse PopulationsJ. Antimicrob. Chemother.20106510.1093/jac/dkq015 123.ThomasE.GhanyM.G.LiangT.J.Review the application and"/>
 <result pre="roles in pathogenesisJ. Microbiol. Immunol. Infect.202010.1016/j.jmii.2020.03.022 128.DongL.HuS.GaoJ.Discovering drugs to treat" exact="coronavirus disease 2019" post="(COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 129.DuY.X.ChenX.P.Favipiravir: Pharmacokinetics and Concerns about Clinical"/>
 <result pre="more than 5000 cases at that date) [8]. Figure 2" exact="Severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) structure. This image contains Servier Medical"/>
 <result pre="https://smart.servier.com. Figure 4 Schematic overview of the steps involved in" exact="SARS-CoV-2 infection" post="from the first contact with the virus until the"/>
</results>
